title: Metastatic spinal cord compression secondary to lung cancer.
abstract: OBJECTIVE
  Metastatic spinal cord compression (MSCC) is a disabling complication to cancer, the optimal treatment for which is not settled. An analysis was performed for all patients with MSCC secondary to lung cancer in East Denmark from 1979 to 1988.
  
  
  METHODS
  The total series included 102 cases with small-cell carcinoma (SCLC; 40%), adenocarcinoma (ACL; 26%), squamous cell carcinoma (SQLC; 18%) and large-cell carcinoma (LCC; 9%). Symptoms, clinical presentations, and therapeutic results are described.
  
  
  RESULTS
  The outcome of treatment depended fundamentally on the patient's neurologic condition at the time of the diagnosis. All patients with SCLC who were able to walk at the time of MSCC remained ambulatory, whereas 15% of the nonambulatory SCLC patients regained walking ability. In non-SCLC, 95% of patients continued to be able to walk, whereas 22% regained the ability to walk. No major differences in the immediate outcome of treatment between the various histologic types of lung cancer and the different treatment modalities were observed; however, 82% of the patients with non-SCLC benefited from treatment with laminectomy followed by radiotherapy (RT) compared with either laminectomy (47%) or RT (39%) alone (P = .03, chi 2 test). The group of patients who were treated with laminectomy followed by RT had a better survival (median value, 3.5; range, 0 to 132 months) than patients who were treated with either laminectomy (median value, 1.5; range, 0 to 32 months) or RT (median value, 1; range, 0 to 59 months) alone (P = .03, log-rank test). No significant difference was observed in survival between the various histologic types of lung cancer (P = .18, log-rank test).
  
  
  CONCLUSIONS
  Despite a short survival, early diagnosis and immediate treatment is crucial because it may preserve the gait function in 97% of lung cancer patients who develop malignant spinal cord compression.
authors.affiliation: Department of Oncology, University Hospital Herlev, Copenhagen, Denmark.
authors.forename: F
authors.initials: F
authors.lastname: Bach
authors.forename: N
authors.initials: N
authors.lastname: Agerlin
authors.forename: J B
authors.initials: JB
authors.lastname: Sørensen
authors.forename: T B
authors.initials: TB
authors.lastname: Rasmussen
authors.forename: P
authors.initials: P
authors.lastname: Dombernowsky
authors.forename: P S
authors.initials: PS
authors.lastname: Sørensen
authors.forename: H H
authors.initials: HH
authors.lastname: Hansen
mesh_terms: D000230:Adenocarcinoma / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000556:secondary; D003131:Combined Modality Therapy; D003718:Denmark / Q000453:epidemiology; D005260:Female; D006801:Humans; D007796:Laminectomy; D015993:Life Tables; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013117:Spinal Cord Compression / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D013125:Spinal Neoplasms / Q000453:epidemiology / Q000556:secondary* / Q000628:therapy*; D016896:Treatment Outcome